Aquyre Biosciences Announces Appointment of F. Samuel Eberts III as CEO and Chairman of the Board of Directors & Founder Bertrand de Poly as Chief Strategy & Technology Officer
3.5.2023 20:04:00 EEST | Business Wire | Press release
Aquyre Biosciences, Inc. today announced the appointment of F. Samuel Eberts III as Chief Executive Officer and Chairman of its Board of Directors. Founder Bertrand de Poly will assume the role of Chief Strategy & Technology Officer, focusing on strategy and technological development, along with his continued service on the board.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230503005760/en/
F. Samuel Eberts III, Chief Executive Officer and Chairman of the Board of Directors (Photo: Business Wire)
This evolution in management aims to take the company to its next stage of growth, building on recent achievements including the acceptance of a clinical study manuscript with Johnson & Johnson at Boston University and Fox Chase Cancer Center, to be presented at the American Thoracic Society meeting in Washington, DC on May 19-24, 2023.
Samuel Eberts brings to Aquyre Biosciences decades of experience at the intersection of healthcare, law, and academia. His varied career includes equity partnership and board, and investment committee membership at a private equity firm whose collaboration with Harvard-affiliated Mass General’s Wellman Center facilitated world-class medical insights, and ongoing engagements as a Partner at Market Street HealthCare Partners, a private equity sponsor for healthcare investments. For 15 years, Sam was part of the senior management team at LabCorp, where he served as Chief Legal Officer, Corporate Secretary, and Senior Vice President of Corporate Affairs, with oversight of regulatory, government relations, and merger and acquisition activities. He is a senior advisor for healthcare investments to Aquyre’s shareholder, Invescore. Sam is also a Senior Lecturing Fellow at Duke University School of Law, a member of the advisory board for the Wilson Center, and has served on the World Policy Institute Advisory Board, the Harvard Law School Corporate Governance Forum, and the John F. Kennedy School of Government Healthcare Policy Leadership Council. He also serves on the board of several non-profit organizations.
“I am delighted that Samuel has agreed to help take Aquyre to the next level of its growth journey as we further refine our technology and scale our partner solutions and corporate operations. I look forward to working with him to help ensure the success of our company,” said Bertrand de Poly.
“I am particularly pleased that among the many shareholders of Aquyre, Canon Medical Systems Corporation, the medical equipment subsidiary of the optical, imaging, and industrial multinational Canon, Inc., is a strategic investor,” said Samuel Eberts. “I am honored to be leading such an impressive collection of people and products and am excited about the potential of Aquyre Biosciences. It is humbling and exciting to be part of an organization that will play an important role in healthcare. We are well positioned to bring a new level of precision in diagnosis of cancer, improving the lives of patients.”
About Aquyre Biosciences
Aquyre Biosciences, Inc is the creator of CelTivity™, the industry leader in two-minute lung biopsy adequacy assessment. Powered by two proprietary technologies including Dynamic Cell Imaging™ (DCI), CelTivity can scan a biopsy and measure intracellular and metabolic activity throughout extracted tissue. This activity is presented in a heatmap, making it easy to interpret. The assessment does not require any cutting or staining, meaning the same tissue assessed for adequacy can go to final pathology to review for cancer, granuloma, lymphocytes, and more. Aquyre Biosciences is headquartered out of Weston, Mass. For more information, please visit www.aquyre.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230503005760/en/
Contact information
Emily Ritacco
Director of Marketing
eritacco@aquyre.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Empire State Building Observation Deck Debuts New Family Bundle Ticket Options13.7.2026 23:30:00 EEST | Press release
The Empire State Building Observation Deck (ESBOD), atop the “World’s Most Famous Building,” announced today new ticket bundle options for families of all ages to save on their visit to the famed New York City landmark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713003884/en/ Empire State Building Observation Deck Debuts New Family Bundle Ticket Options Groups of four who purchase the new Family Ticket Bundle can save up to 20 percent on tickets to the Empire State Building’s iconic 86th and 102nd Floor Observation Decks, with options for express access and flex admission. The Family Ticket Bundle is available online only. “The Empire State Building Observation Deck is one of the best activities for families in NYC with immersive, educational museum exhibits and Manhattan’s best skyline views,” said Dan Rogoski, observatory general manager. “There is no better place to make family memories than at the #1 attraction in
Kinaxis Inc. to Host Second Quarter 2026 Financial Results Conference Call on August 6, 202613.7.2026 23:05:00 EEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, today announced that it has scheduled a conference call to discuss its financial results for the second quarter ended June 30, 2026. The call will be hosted on Thursday, August 6, 2026, at 8:30 a.m. Eastern Time by Razat Gaurav, Chief Executive Officer, and Peter Yaraskavitch, Vice President, Financial Planning and Analysis, followed by a question and answer period. The Company will report its financial results for the second quarter after the close of markets on Wednesday, August 5, 2026. CONFERENCE CALL DETAILS DATE: Thursday, August 6, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/854228135 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietar
PagerDuty Announces Arnaud Lagarde, Vice President of EMEA13.7.2026 23:05:00 EEST | Press release
PagerDuty, Inc. (NYSE: PD), a leader in AI-first operations management, today announced the appointment of Arnaud Lagarde as vice president of EMEA. Lagarde will lead PagerDuty’s next phase of growth in the EMEA region, bringing the entire incident management lifecycle to customers across EMEA to solve their biggest digital challenges. “We are thrilled to appoint Arnaud as vice president of EMEA, since he brings a wealth of enterprise sales relationships and years of experience growing this region,” said Todd McNabb, chief revenue officer at PagerDuty. “Arnaud brings a specific combination of deep technical expertise and leadership that will be critical for PagerDuty’s customers, partners and employees. He is a great fit for PagerDuty and we look forward to his impact.” Lagarde brings to the role over 20 years of experience spanning companies like Automation Anywhere, CA Technologies and BMC. Over the past two decades, he has worked closely with founders, investors and executive teams
Samos Energy Acquisition Corporation Announces Closing of $230 Million Initial Public Offering13.7.2026 22:42:00 EEST | Press release
Samos Energy Acquisition Corporation (the “Company”) announced today the closing of its initial public offering (“IPO”) of 23,000,000 units, including the full exercise by the underwriters of their overallotment option to purchase an additional 3,000,000 units. The offering was priced at $10.00 per unit, resulting in gross proceeds to the Company of $230,000,000. The units began trading on the New York Stock Exchange (the “NYSE”) under the ticker symbol “SAMO.U” on July 10, 2026. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant, with each whole warrant entitling the holder thereof to purchase one of the Company’s Class A ordinary shares at an exercise price of $11.50 per share. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on the NYSE under the symbols “SAMO” and “SAMO.WS,” respectively. Of the proceeds received from the consummation of the initial public offerin
Kiinalaiset ja EU:n kansalaiset suhtautuvat luottavaisesti Kiinan ja EU:n tulevan yhteistyön näkymiin: GT survey13.7.2026 21:47:00 EEST | Tiedote
Kiinalla ja Euroopan unionilla on ollut viralliset diplomaattisuhteet jo yli puolen vuosisadan ajan. Diplomaattisuhteiden solmimisesta lähtien suhteet ovat kehittyneet kattavaksi strategiseksi kumppanuudeksi, ja Kiinan ja EU:n välisistä suhteista on tullut yksi maailman vaikutusvaltaisimmista kahdenvälisistä suhteista. Kiinan lisäksi Global Times Institute (GTI) toteutti 16.10.–4.11.2025 kyselytutkimuksen 20 EU:n jäsenvaltiossa, kuten Tanskassa, Ruotsissa, Espanjassa, Belgiassa ja Saksassa. Kysely tehtiin 21 kielellä, mukaan lukien espanjaksi, ranskaksi, saksaksi ja kiinaksi. Vastauksia saatiin yli 16 300, ja ne hyväksyttiin tutkimukseen. Kyselyn tulokset osoittavat, että enemmistö sekä Kiinan että EU:n kansalaisista on kiinnostunut toistensa kulttuureista, suhtautuu luottavaisesti Kiinan ja EU:n talous- ja kauppayhteistyön tulevaisuuteen sekä kannattaa Kiinan ja EU:n välisen yhteistyön vahvistamista globaalissa hallinnassa. Korkea tietoisuus ja halukkuus vuorovaikutukseen Tämä kysely
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom